Evoke Pharma Announces Closing of $7.5 Million Public Offering
"We are pleased to have closed this offering with these fundamental, healthcare-oriented institutional investors," stated Evoke Pharma Chief Executive Officer Dave Gonyer.
- "We are pleased to have closed this offering with these fundamental, healthcare-oriented institutional investors," stated Evoke Pharma Chief Executive Officer Dave Gonyer.
- If the Series A Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
- If the Series B Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
- Evoke intends to use the net proceeds from the public offering for working capital and general corporate purposes.